Adam Levy Biography and Net Worth

CFO of Acrivon Therapeutics

Adam D. Levy is Chief Financial Officer at Acrivon Therapeutics, Inc. Previously, he served as Senior Vice President of Investor Relations at Zentalis Pharmaceuticals, Inc. Prior to Zentalis, he was Senior Vice President of Investor Relations and Corporate Communications at Turning Point Therapeutics, where he was part of the team that delivered a $4.1B transaction when the company was acquired by Bristol Myers Squibb in 2022. Earlier in his career he held positions of increasing responsibility in Corporate Strategy and Corporate Development at Pfizer Inc., Novartis AG, Alexion Pharmaceuticals and Gilead Sciences, where he was Head of Corporate Strategy. Adam also served as an Engagement Manager at McKinsey and Company, focusing on supporting clients in the pharmaceutical industry. Adam received an MBA from the Kellogg School of Management at Northwestern University, a PhD in Molecular Biology from the University of Illinois at Chicago, and a BS in Genetics from the University of Illinois at Urbana-Champaign.

What is Adam D. Levy's net worth?: The estimated net worth of Adam D. Levy is at least $121.12 thousand as of August 4th, 2026. Dr. Levy owns 66,008 shares of Acrivon Therapeutics stock worth more than $121,125 as of September 18th. This net worth estimate does not reflect any other investments that Dr. Levy may own. Learn More about Adam D. Levy's net worth.
How do I contact Adam D. Levy?: The corporate mailing address for Dr. Levy and other Acrivon Therapeutics executives is 480 Arsenal Way, Suite 100, Watertown, MA, 02472. Acrivon Therapeutics can also be reached via phone at 617-207-8979 and via email at [email protected]. Learn More on Adam D. Levy's contact information.
Has Adam D. Levy been buying or selling shares of Acrivon Therapeutics?: During the past quarter, Adam D. Levy has sold $1,792.94 in shares of Acrivon Therapeutics stock. Most recently, Adam D. Levy sold 1,142 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $1.57, for a transaction totalling $1,792.94. Following the completion of the sale, the chief financial officer now directly owns 66,008 shares of the company's stock, valued at $103,632.56. Learn More on Adam D. Levy's trading history.
Who are Acrivon Therapeutics' active insiders?: Acrivon Therapeutics' insider roster includes Peter Blume-Jensen (CEO), Eric Devroe (COO), and Adam Levy (CFO). Learn More on Acrivon Therapeutics' active insiders.
Are insiders buying or selling shares of Acrivon Therapeutics?: In the last twelve months, Acrivon Therapeutics insiders bought shares 3 times. They purchased a total of 67,832 shares worth more than $114,534.40. In the last twelve months, insiders at the sold shares 7 times. They sold a total of 18,253 shares worth more than $38,850.00. The most recent insider tranaction occured on August, 25th when CEO Peter Blume-Jensen sold 14,036 shares worth more than $31,019.56. Insiders at Acrivon Therapeutics own 10.5% of the company. Learn More about insider trades at Acrivon Therapeutics.
Information on this page was last updated on 8/25/2026.

Adam D. Levy Insider Trading History at Acrivon Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/4/2026	Sell	1,142	$1.57	$1,792.94	66,008
1/14/2026	Buy	8,832	$1.70	$15,014.40	20,983

Adam D. Levy Buying and Selling Activity at Acrivon Therapeutics

Acrivon Therapeutics Company Overview

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Today's Range

Now: $1.87

$1.69

$1.90

50 Day Range

MA: $1.88

$1.43

$2.39

2 Week Range

Now: $1.87

$1.27

$3.56

Volume

366,860 shs

Average Volume

918,161 shs

Market Capitalization

$79.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92